Amphotericin
Amphotericin.JPG

Amphotericin

CLINICAL USE

Antifungal agent:
  • Systemic fungal infections (yeasts and yeast-like fungi including Candida albicans

    DOSE IN NORMAL RENAL FUNCTION

    5 mg/kg/day for at least 14 days (see individual product data sheet)

    PHARMACOKINETICS

  • Molecular weight                           : 924.1
  • %Protein binding                           : 90
  • %Excreted unchanged in urine     : <1
  • Volume of distribution (L/kg)       : 2286
  • half-life – normal/ESRD (hrs)      : 173.4/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                : Not dialysed. Dose as in normal renal function
  • HD                     : Not dialysed. Dose as in normal renal function
  • HDF/high flux   : Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      : Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Ciclosporin: increased nephrotoxicity
  • Tacrolimus: increased nephrotoxicity
  • Increased risk of nephrotoxicity with aminoglycosides and other nephrotoxic agents and cytotoxics
  • Cardiac glycosides: increased toxicity if hypokalaemia occurs
  • Corticosteroids: increased risk of hypokalaemia (avoid concomitant use unless corticosteroids are required to control reactions)
  • Flucytosine: enhanced toxicity in combination with amphotericin

    ADMINISTRATION

    Reconstition

    See individual data sheet. Prepare intermittent infusion in glucose 5% (incompatible with sodium chloride 0.9%, electrolytes or other drugs).
  • Dilute to a concentration of 1–2 mg/mL

    Route

    IV infusion

    Rate of Administration

    2.5 mg/kg/hour

    Comments

  • Paracetamol and parenteral pethidine may alleviate rigors associated with amphotericin administration. Can also use antihistamines to control reactions
  • Flush existing IV line with glucose 5% before and after infusion administration
  • For patients on CAV/VVHD, amphotericin should be given into the venous return of the dialysis circuit Should be given post dialysis

    OTHER INFORMATION

    *** AMPHOTERICIN IS HIGHLY NEPHROTOXIC ***
  • Can cause distal tubular acidosis
  • May cause polyurea, hypovolaemia, hypokalaemia and acidosis.
  • Amphotericin and flucytosine act synergistically when co-administered enabling lower doses to be used effectively
  • A test dose of amphotericin is recommended at the beginning of a new course (1 mg over 15 minutes)
  • Monitor renal function, full blood count, potassium, magnesium and calcium levels
  • Liposomal amphotericin is considerably less nephrotoxic compared with conventional amphotericin B, but is considerably more expensive



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs